CAMBRIDGE, MASS. & OSAKA, JAPAN--( / ) June 01, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone.
The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemia (HR-CMML) and low-blast acute myeloid leukemia (LB-AML). Though it did not achieve pre-defined statistical significance for the primary endpoint of OS, treatment with the pevonedistat combination demonstrated a numerically longer OS compared with azacitidine alone and a trend towards benefit in EFS, defined as death or transformation to AML.
“We are very optimistic about pevonedistat based on these Phase 2 results, particularly in the higher-risk MDS subgroup, which showed that the combination of pevonedistat and azacitidine provided benefit to patients at the level of several key endpoints, without introducing additional safety concerns. Not only did the combination demonstrate longer survival, but patients in the higher-risk MDS subgroup also achieved higher response rates and increased transfusion independence,” said Christopher Arendt, Head, Oncology Therapeutic Area Unit, Takeda. “We are looking forward to building on this dataset with our Phase 3 PANTHER trial, which completed enrollment last fall, and will support registration for pevonedistat globally.”
There have been no treatment advancements for HR-MDS in more than a decade and current treatment options provide limited benefit. Pevonedistat could be the first new treatment option for these patients.
“It’s exciting to see such encouraging results in the Pevonedistat-2001 trial, particularly in higher-risk MDS, an aggressive type of MDS associated with poor prognosis, diminished quality of life, and higher chance of transformation to AML,” said Lionel Ades, MD, PhD, Hopital Saint-Louis, and a primary investigator of the Pevonedistat-2001 study. “Adding pevonedistat to the current standard of care in higher-risk MDS doubled complete remission rates, increased the duration of response and improved long-term outcomes with a safety profile similar to azacitidine alone, which may address a significant need for people living with this disease.”
Primary Results from the Phase 2 Pevonedistat-2001 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS), Higher-Risk Chronic Myelomonocytic Leukemia (HR-CMML) and Low-Blast Acute Myeloid Leukemia (LB-AML).
Key findings, to be presented by Dr. Lionel Ades, include:
· Intent to treat population (n=120):
- Median OS was 21.8 months (mos.) in the pevonedistat combination arm, vs. 19.0 mos. with azacitidine alone (HR 0.802; p = 0.334).
- EFS trended longer in the pevonedistat combination arm vs. azacitidine alone with a median of 21.0 mos. vs. 16.6 mos.
· HR-MDS Subgroup (n=67):
- Median OS in the pevonedistat combination arm alone was 23.9 mos. vs. 19.1 mos. with azacitidine alone.
- Median EFS in the pevonedistat combination arm was 20.2 mos. vs. 14.8 mos. with azacitidine alone.
- Overall response rate (ORR) in the pevonedistat combination arm was 79.3% vs. 56.7% with azacitidine alone.
- CR rate in the pevonedistat combination arm was 51.7% vs. 26.7% with azacitidine alone.
- Median duration of response (DoR) in the pevonedistat combination arm was 34.6 months vs. 13.1 mos. with azacitidine alone.
- Of the patients who were red blood cell (RBC) transfusion dependent at baseline, 69.2% receiving pevonedistat plus azacitidine vs. 50.0% receiving azacitidine alone became transfusion independent.
· LB-AML (n=36) & HR-CMML (n=17) Subgroups:
- Median OS in LB-AML was 23.6 mos. in the pevonedistat combination arm vs. 16.0 mos. with azacitidine alone.
- Median OS and EFS in HR-CMML favored the azacitidine alone arm, which may be due to low sample size and/or greater patient heterogeneity.
· Safety data includes:
- The safety profile of pevonedistat combined with azacitidine was similar to azacitidine alone, and did not lead to increased myelosuppression.
- The most common grade ≥3 AEs across both arms were neutropenia (33% vs. 27%), febrile neutropenia (26% vs. 29%), decreased neutrophil count (21% vs. 10%), anemia (19% vs. 27%), thrombocytopenia (19% vs. 23%), and pneumonia (12% vs. 10%).
- On-study deaths occurred in 9% of patients in the pevonedistat combination arm versus 16% with azacitidine alone.
About the Pevonedistat-2001 Trial
Pevonedistat-2001 (NCT02610777) is a global, randomized, controlled, open-label, multi-center, Phase 2 clinical trial designed to evaluate the safety and efficacy of pevonedistat in combination with azacitidine versus single-agent azacitidine in patients with higher-risk MDS or CMML, or low-blast AML, who were ineligible for stem cell transplant and have not received prior therapies. Approximately 120 participants were enrolled worldwide. The primary endpoint of the trial is OS.
Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor, which blocks modifications of select proteins. Pevonedistat treatment disrupts cell cycle progression and cell survival, leading to cell death in cancers including leukemias. Pevonedistat in combination with azacitidine demonstrated antitumor activity in preclinical studies and was well tolerated, with promising clinical activity, in a Phase 1 study of patients with AML. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML, and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy and is also being explored in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax.
About MDS, CMML and AML
MDS, CMML and AML are rare forms of bone marrow-related cancer caused by irregular blood cell production within the bone marrow. These cancers most commonly affect older patients, with the median age of diagnosis ranging from 60 to 74 years. As a result of this irregular production, a person with MDS, CMML or AML does not have enough normal red blood cells, white blood cells and/or platelets in circulation. Symptoms for MDS, CMML and AML are often vague and related to low blood counts, and may include fatigue, shortness of breath, easy bruising or bleeding, loss of appetite, weakness, pale skin, fever and frequent or severe infections.
There are several classifications of MDS - very low risk to very high risk - determined by blood counts, blast counts, mutations and cytogenetics. Higher-risk disease is defined as intermediate, high or very high risk on the International Prognostic Scoring System - Revised (IPSS-R), and these patients have a poorer prognosis. Approximately 40% of patients with HR-MDS transform to AML, an aggressive form of acute leukemia in adults, with poor outcomes.
Takeda’s Commitment to Oncology
Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information?D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
LONDON, 섹스신 LONDON,수저넷 홍도깨비 KINGDOM AND CHICAGO, IL--() July 연지동풀팟홀덤 명품비키니수영복 26, 2012 -- Fidessa group plc (LSE: FDSA), provider of high-performance trading, investment management and information 섹스신 LONDON,for the world's financial community, today announced that Newedge, one of the leading forces in multi-asset execution globally, has selected the Fidessa trading platform and order management system for 이격도 LONDON,global derivatives and equity trading business.
The first phase of this project, covering trading hubs in London and Chicago, is now live. Subsequent phases will see the 손빨래 Therolled out across other hubs in Asia this year. The platform will provide Newedge with a multi-asset trading workflow solution across 스코어보드닷컴 Thefront and middle-office operations - 연지동풀팟홀덤 집컴퓨터공유 incorporating global order management, access to Newedge trading 연지동풀팟홀덤 밤꽃 algorithms, FIX connectivity and smart order routing tools. Fidessa will also supply comprehensive, global market data as part of the deal, as well as low-latency gateways to access over 100 derivatives and cash equity markets. Fixed Income will be added to the 연지동풀팟홀덤 platform in 2013. This distributed solution has been fully 수저넷 색칠공부프린트 outsourced to Fidessa, leveraging their proven track record in servicing tier one financial institutions.
Nicholas Garrow, Global Head of eSolutions 스코어보드닷컴 NicholasNewedge, 수저넷 야군19 commented: “We are extremely excited to be working with Fidessa to deliver a world class execution platform which will underpin the growth 수저넷 네토닷컴 of our equities, futures and options business globally. 수저넷 밤의신 Fidessa's 연지동풀팟홀덤 sophisticated multi-asset workflow offering - including an integrated, multi-asset algorithmic trading engine and centralised pre-trade risk and monitoring tools - will play an 연지동풀팟홀덤 네트워크공유방법 integral role to deliver next-generation capabilities to our global clients spanning all asset classes.”
쿨애니구 StephenBarrow, Global 연지동풀팟홀덤 Sales Director at Fidessa, 수저넷 added: “Newedge is one of the premier multi-asset brokerage firms in the world and we are very proud to be working with them. We believe that the firms that can harness the regulatory momentum that is bringing together the worlds of OTC and exchange-traded derivatives will have a significant competitive advantage. Newedge and Fidessa share the same vision as to how this can be achieved through smarter workflow, integrated risk 수저넷 management and compliance, and streamlined execution. In addition, our 수저넷 기가공유사이트 야킹19 Stephendeployment, hosting and support capabilities mean that we can provide Newedge with substantial operational efficiencies as the firm leverages the new landscape, both now and in the future.”
Fidessa's award-winning multi-asset 연지동풀팟홀덤 flickrapi trading solutions serve over 27,000 users across 950 clients around the world. The Fidessa connectivity network carries 연지동풀팟홀덤 JAVBUS 캣알바 Fidessa's$10 trillion of 수저넷 flickr로그인 order flow per year and connects 2,900 buy-sides to 700 brokers covering 200 markets globally.
About 연지동풀팟홀덤 엑스비디오 수저넷 엑스비디오 크레이지볼콕링사용법동영상 About수저넷 플리커로그인
Newedge, 파워업맨마사지젤판매사이트 Newedge,50/50 joint venture between Societe Generale and Credit Agricole CIB, is a major force in global multi-asset brokerage business, with a world-leading position in the execution and clearing of listed derivative products. With a presence in more than 연지동풀팟홀덤 튜브8 20 연지동풀팟홀덤 레드튜브 locations in 16 countries, Newedge offers a full range 수저넷 watchjavonline of clearing and execution services covering options and futures contracts for financial products and commodities, as well as for money market instruments, bonds, FX, equities, and commodities on OTC markets. Newedge provides a range of value added services, including prime brokerage, asset financing, an electronic platform for trading and order routing, cross margining, and the centralized 수저넷 즐밤 reporting of client portfolios. Newedge, which primarily serves 암사1동홀덤 Newedge,clients, provides access to guMglRG Newedge,than 85 exchanges. Newedge's 3,000+ employees form a close-knit, multinational team that can innovatively respond to its 연지동풀팟홀덤 AV피그 clients in fast-moving markets. For more information, visit
New 연지동풀팟홀덤 technology, new regulation, new challenges: making money in today‘s financial 연지동풀팟홀덤 조개모아 markets is 고추맛집 Newabout staying ahead of the curve. Having the capability to spot new trends and act fast turns change into opportunity. That’s why 85% of the world‘s premier financial institutions trust Fidessa to provide them 연지동풀팟홀덤 with their multi-asset trading and investment infrastructure, their market data and analysis, and their decision making and workflow technology. It’s also why $10 trillion worth of transactions flow across our global network each year. Because we‘re the market leader, we can also offer unique access to the world’s largest and most 수저넷 오피걸스동인지 New엠스팟 Newcommunity of buy-side and sell-side professionals, from global institutions and 수저넷 investment banks to boutique brokers and niche hedge funds.
Fidessa is a global business with scale, resilience, ambition and expertise. We‘ve delivered around 30% compound 마츠시타사에코 Fidessasince our stock market listing in 1997 and we’re recognised as the thought leader 수저넷 in our space. We set the benchmark with our unrivalled set of mission-critical products and services and, uniquely, 연지동풀팟홀덤 지노야 serve both 수저넷 KAOTIC the buy-side 사형 Fidessasell-side communities. Ongoing investment 수저넷 BESTGORE in our leading-edge, integrated 연지동풀팟홀덤 CUTSCENES solutions ensures Fidessa remains the industry's number one choice.
Fidessa® 연지동풀팟홀덤 문채원데뷔작 is 강원랜드카지노홈페이지 Fidessa®registered trademark of 수저넷 섹툰 Fidessa 수저넷 야플릭스 group plc.
All product 연지동풀팟홀덤 초콜렛레드 and company names herein 수저넷 may 수저넷 f/w트랜드 be trademarks of their 토렌트뷰 Allowners. 연지동풀팟홀덤 최신헤어 수저넷 최신헤어
“Newedge” refers to Newedge Group SA and all of its worldwide branches and subsidiaries. Newedge Group in France 수저넷 밍키넷야한만화 and its foreign 연지동풀팟홀덤 이태임 branches are authorized by the Autorite de Controle Prudentiel and Autorite des 무료 실시간 tv 어플 “Newedge”Financiers 연지동풀팟홀덤 in France. Newedge UK Financial Limited is authorized and regulated by the Financial Services Authority. Newedge Group (Frankfurt, Zurich, Geneva and Dubai branches) and Newedge UK Financial Limited do not deal with, or for, Retail Clients (as defined under MiFID, FSA rules and Dubai Financial Services Authority). Only Newedge USA, LLC is a member of FINRA and SIPC (SIPC only pertains to securities-related transactions and positions). Only Newedge Canada Inc. is a member of the Canadian Investor Protection Fund. Not all products or services are available from all 연지동풀팟홀덤 먹튀헌터 Newedge organizations or personnel."
"All information, prices or projections are subject to change without notice. Some financial products and investments are subject to fluctuations in price and or value and investors 수저넷 스페이스TV may get back less than originally invested. 무료 실시간 tv 어플 "Alland options, as well as certain other 수저넷 스포츠중계해골TV financial instruments, are speculative products and the risk of loss can be substantial. Consequently, only risk capital should be used to trade futures and options and other speculative products. Investors should fully understand the risks and potential losses and seek their own independent 무료 실시간 tv 어플 "Alland trading advice having regard to their objectives, financial situation and needs. This information is not intended to be construed as investment advice.Korea Newswire 연지동풀팟홀덤 distributes your news across every media channels through the industry’s largest press release distribution 밤토끼넷 "All
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.